G-Pen Compared to Glucagen Hypokit for Severe Hypoglycemia Rescue in Adults With Type 1 Diabetes
| Status: | Recruiting |
|---|---|
| Conditions: | Endocrine, Diabetes, Diabetes |
| Therapuetic Areas: | Endocrinology |
| Healthy: | No |
| Age Range: | 18 - 75 |
| Updated: | 2/17/2019 |
| Start Date: | September 27, 2018 |
| End Date: | April 2019 |
| Contact: | Martin J Cummins |
| Email: | mcummins@xerispharma.com |
| Phone: | 806-282-2120 |
G-Pen (Glucagon Injection) Compared to GlucaGen® Hypokit® (Glucagon) for Induced Hypoglycemia Rescue in Adults With T1D: A Phase 3 Multi-center, Randomized, Controlled, Single Blind, 2-way Crossover Study to Evaluate Efficacy and Safety
This is a multi-center, randomized, controlled, single-blind, two-way crossover efficacy and
safety study in subjects with Type 1 diabetes mellitus. The study involves two daytime
clinical research center (CRC) visits with random assignment to receive G-Pen glucagon 1 mg
during one period and Novo Glucagon 1 mg during the other. Each daytime visit is preceded by
an overnight stay in the CRC. In the morning of the inpatient study visit, the subject is
brought into a state of severe hypoglycemia through IV administration of regular insulin
diluted in normal saline. After a hypoglycemic state with plasma glucose < 54 mg/dL (3
mmol/L) is verified, the subject is administered a dose of G-Pen or Novo Glucagon via
subcutaneous injection. Plasma glucose levels are monitored for up to 180 minutes
post-dosing, with a value of >70.0 mg/dL (3.89 mmol/L) or an increase of > 20 mg/dL (>1.11
mmol/L) within 30 minutes of glucagon administration indicating a positive response. After 3
hours, the subject is given a meal and discharged when medically stable. After a wash-out
period of 7 to 28 days, subjects return to the CRC, and the procedures are repeated with each
subject crossed over to the other treatment. A follow-up visit as a safety check is conducted
2-7 days following administration of the final dose of study drug.
safety study in subjects with Type 1 diabetes mellitus. The study involves two daytime
clinical research center (CRC) visits with random assignment to receive G-Pen glucagon 1 mg
during one period and Novo Glucagon 1 mg during the other. Each daytime visit is preceded by
an overnight stay in the CRC. In the morning of the inpatient study visit, the subject is
brought into a state of severe hypoglycemia through IV administration of regular insulin
diluted in normal saline. After a hypoglycemic state with plasma glucose < 54 mg/dL (3
mmol/L) is verified, the subject is administered a dose of G-Pen or Novo Glucagon via
subcutaneous injection. Plasma glucose levels are monitored for up to 180 minutes
post-dosing, with a value of >70.0 mg/dL (3.89 mmol/L) or an increase of > 20 mg/dL (>1.11
mmol/L) within 30 minutes of glucagon administration indicating a positive response. After 3
hours, the subject is given a meal and discharged when medically stable. After a wash-out
period of 7 to 28 days, subjects return to the CRC, and the procedures are repeated with each
subject crossed over to the other treatment. A follow-up visit as a safety check is conducted
2-7 days following administration of the final dose of study drug.
Inclusion Criteria:
1. Males and non-pregnant females diagnosed with type 1 diabetes (T1D) for at least 24
months.
2. Current usage of daily insulin treatment that includes having an assigned "correction
factor" for managing hyperglycemia.
3. Age 18 to 75 years, inclusive.
4. Random serum C-peptide concentration < 0.6 ng/mL.
5. Willingness to follow all study procedures, including attending all clinic visits.
6. Subject has provided informed consent as evidenced by a signed and dated informed
consent form (ICF) completed before any trial-related activities occur.
Exclusion Criteria:
1. Pregnancy
2. Glycated hemoglobin (HbA1c) > 10% at Screening.
3. Body mass index (BMI) > 40 kg/m2.
4. Renal insufficiency (serum creatinine greater than 3.0 mg/dL) or end-stage renal
disease requiring renal replacement therapy.
5. Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) equal to or
greater than 3 times the upper limit of normal.
6. Hepatic synthetic insufficiency as defined as a serum albumin of less than 3.0 g/dL.
7. Hematocrit < 30%.
8. Blood pressure (BP) readings at Screening where systolic blood pressure (SBP) < 90 or
> 150 mm Hg, and diastolic blood pressure (DBP) < 50 or > 100 mm Hg.
9. Clinically significant electrocardiogram (ECG) abnormalities.
10. Use of total insulin dose per day > 2 U/kg.
11. Inadequate venous access.
12. Congestive heart failure, New York Heart Association (NYHA) class III or IV.
13. History of myocardial infarction, unstable angina, or revascularization within the
past 6 months.
14. History of a cerebrovascular accident in the past 6 months or with major neurological
deficits.
15. Active malignancy within 5 years from Screening, except basal cell or squamous cell
skin cancers. Any history of breast cancer or malignant melanoma will be exclusionary.
16. Major surgical operation within 30 days prior to Screening.
17. Current seizure disorder (other than with suspect or documented hypoglycemia).
18. Current bleeding disorder, treatment with warfarin, or platelet count below 50 × 109
per liter.
19. History of pheochromocytoma or disorder with increased risk of pheochromocytoma
(multiple endocrine neoplasia type 2 (MEN 2), neurofibromatosis, or Von Hippel-Lindau
disease).
20. History of insulinoma.
21. History of allergies to glucagon or glucagon-like products, or any history of
significant hypersensitivity to glucagon or any related products or to any of the
excipients (DMSO and trehalose) in the investigational formulation.
22. History of glycogen storage disease.
23. Subject tests positive for human immunodeficiency virus (HIV), hepatitis C virus
(HCV), or hepatitis B virus (HBV) infection (hepatitis B surface antigen positive
[HBsAg+]) at Screening.
24. Active substance other than tetrahydrocannabinol (THC) or alcohol abuse (more than 21
drinks per week for male subjects or 14 drinks per week for female subject).
25. Administration of glucagon within 7 days of Screening.
26. Participation in other studies involving administration of an investigational drug or
device within 30 days or 5 half-lives, whichever is longer, before Screening for the
current study and during participation in the current study.
27. Any other reason the Investigator deems exclusionary.
We found this trial at
5
sites
Atlanta, Georgia 30309
Principal Investigator: Bruce Bode, MD
Phone: 404-355-4393
Click here to add this to my saved trials
Graz,
Principal Investigator: Thomas Pieber, PhD
Phone: 43-316-385-82383
Click here to add this to my saved trials
Las Vegas, Nevada 89113
Principal Investigator: Samer Nakhle, MD
Phone: 702-963-1580
Click here to add this to my saved trials
Renton, Washington 98057
Principal Investigator: Leslie Klaff, MD, PhD
Phone: 425-251-1720
Click here to add this to my saved trials
Walnut creek, California 94598
Principal Investigator: Mark Christiansen, MD
Phone: 925-930-7267
Click here to add this to my saved trials